These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37695339)

  • 1. Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Wang X; Zhang F; Zhang Y; Zhang J; Sheng Y; Wang W; Li Y
    Osteoporos Int; 2023 Dec; 34(12):2013-2025. PubMed ID: 37695339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
    Li X; Li T; Cheng Y; Lu Y; Xue M; Xu L; Liu X; Yu X; Sun B; Chen L
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3170. PubMed ID: 30983141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Wang J; Li X; Li Y; Lei C
    BMC Endocr Disord; 2024 Apr; 24(1):52. PubMed ID: 38658986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials.
    Cheng L; Li YY; Hu W; Bai F; Hao HR; Yu WN; Mao XM
    Diabetes Metab; 2019 Oct; 45(5):436-445. PubMed ID: 30738154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.
    Jackson K; Moseley KF
    Curr Osteoporos Rep; 2020 Oct; 18(5):439-448. PubMed ID: 32710428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Zhang S; Qi Z; Wang Y; Song D; Zhu D
    Front Endocrinol (Lausanne); 2023; 14():1203666. PubMed ID: 37465122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
    Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
    Trials; 2020 May; 21(1):379. PubMed ID: 32370806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
    Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
    Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
    Ruanpeng D; Ungprasert P; Sangtian J; Harindhanavudhi T
    Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28440590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
    Tang HL; Li DD; Zhang JJ; Hsu YH; Wang TS; Zhai SD; Song YQ
    Diabetes Obes Metab; 2016 Dec; 18(12):1199-1206. PubMed ID: 27407013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    Wei Q; Xu X; Guo L; Li J; Li L
    Front Endocrinol (Lausanne); 2021; 12():635556. PubMed ID: 34220701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
    Tang H; Zhang X; Zhang J; Li Y; Del Gobbo LC; Zhai S; Song Y
    Diabetologia; 2016 Dec; 59(12):2546-2551. PubMed ID: 27628105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
    Alba M; Xie J; Fung A; Desai M
    Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
    Azharuddin M; Adil M; Ghosh P; Sharma M
    Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Fu R; Liu H; Ma Y; Qiu X; Dong Z
    Ann Palliat Med; 2021 Jun; 10(6):6467-6481. PubMed ID: 34118855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.